Arrowhead Pharmaceuticals's market cap is currently ―. The company's EPS TTM is $-2.771; its P/E ratio is -8.66; Arrowhead Pharmaceuticals is scheduled to report earnings on May 7, 2024, and the estimated EPS forecast is $-0.48. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22
Income Statement	-
Total Revenue	$ 3.55M	$ 16.10M	$ 15.82M	$ 146.27M	$ 62.55M
Gross Profit	$ 3.55M	$ 16.10M	$ 15.82M	$ 146.27M	$ 62.55M
EBIT	$ -133.32M	$ -100.88M	$ -98.22M	$ 52.73M	$ -41.63M
EBITDA	$ -129.06M	$ -97.02M	$ -94.95M	$ 55.40M	-
Net Income Common Stockholders	$ -132.88M	$ -109.68M	$ -102.95M	$ 48.67M	$ -41.33M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 162.06M	$ 292.74M	$ 451.70M	$ 481.00M	$ 501.83M
Total Assets	$ 626.29M	$ 765.55M	$ 795.86M	$ 891.31M	$ 891.49M
Total Debt	$ 118.58M	$ 115.17M	$ 82.73M	$ 82.78M	$ 82.13M
Net Debt	$ -43.49M	$ -177.56M	$ -368.97M	$ -398.22M	$ -419.70M
Total Liabilities	$ 452.57M	$ 478.39M	$ 413.87M	$ 426.20M	$ 891.49M
Stockholders Equity	$ 160.41M	$ 271.34M	$ 364.83M	$ 446.77M	$ 377.04M
Cash Flow	-
Free Cash Flow	$ -186.50M	$ -89.16M	$ -68.05M	$ -58.98M	$ -114.43M
Operating Cash Flow	$ -117.84M	$ -25.26M	$ -21.45M	$ -31.67M	$ -75.52M
Investing Cash Flow	$ 64.84M	$ 30.51M	$ -9.90M	$ -36.06M	$ -80.69M
Financing Cash Flow	$ 267.00K	$ 152.00K	$ 1.80M	$ 520.00K	$ 250.58M

Currency in USD

Arrowhead Pharmaceuticals Earnings and Revenue History

Income Statement >

Arrowhead Pharmaceuticals Debt to Assets

Balance Sheet >

Arrowhead Pharmaceuticals Cash Flow

Cash Flow >

Arrowhead Pharmaceuticals Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing